托特罗定联合氟哌噻吨美利曲辛治疗膀胱过度活动症临床观察

Clinical observation of tolterodine combined with flupentixol melitracen in the treatment of patients with overactive bladder

目的 探讨托特罗定联合氟哌噻吨美利曲辛治疗女性膀胱过度活动症（OAB）的临床疗效及安全性.方法 选择确诊为女性膀胱过度活动症患者84例,采用随机数字表法分为观察组和对照组各42例.观察组42例采用托特罗定联合氟哌噻吨美利曲辛治疗,对照组42例单用托特罗定治疗,4周后记录并比较两组临床疗效.结果 观察组总有效率明显优于对照组（95.24％比76.19％,x2=6.291,P＜0.05）；两组平均24h排尿次数、平均24 h尿失禁次数、初始尿意容量及最大膀胱压容量差异均有统计学意义（均P＜0.05）.结论 托特罗定联合氟哌噻吨美利曲辛治疗女性膀胱过度活动症具有疗程短、疗效高、不良反应少等优点.

Objective To investigate the clinical efficacy and safety of tolterodine combined with flupentixol melitracen in the treatment of women with overactive bladder （OAB）.Methods 84 female patients with OAB were chosen and randomly divided into the observation group and the control group.42 cases in observation group were treated with tolterodine combined with flupentixol melitracen.42 cases in control group were only treated with tolterodine.The clinical efficacy was recorded and compared after treatment for 4 weeks.Results The total effective rate of the observation group was higher than the control group （95.24% vs 76.19%,x2 =6.291,P 〈 0.05）.The 24h frequency of urination,the average 24h number of incontinence episodes,initial urinate capacity and maximum bladder pressure capacity had statistically significant differences between the two groups （all P 〈 0.05）.Conclusion Tolterodine combined with flupentixol melitracen in the treatment of women with OAB has advantages of short course of treatment,excellent efficacy,and few side effects.